Skip Navigation LinksHome > May 2014 - Volume 17 - Issue 3 > Acylated and unacylated ghrelin administration to blunt musc...
Current Opinion in Clinical Nutrition & Metabolic Care:
doi: 10.1097/MCO.0000000000000049
TRANSLATIONAL RESEARCH IN WASTING DISEASES: Edited by Vickie E. Baracos, Claude Pichard and Didier Attaix

Acylated and unacylated ghrelin administration to blunt muscle wasting

Reano, Simone; Graziani, Andrea; Filigheddu, Nicoletta

Collapse Box


Purpose of review: Muscle wasting is a comorbidity often associated with a wide range of disorders that severely affects patient prognosis and quality of life. Ghrelin, through its receptor GHSR-1a, stimulates appetite and growth hormone (GH) release. Several studies indicate that ghrelin administration is a valid treatment for cachexia because it improves muscle mass and function, likely by restoring a positive energy balance.

Recent findings: In addition to its GHSR-1a-mediated effects on muscle mass, ghrelin acts directly on skeletal muscle, wherein it exerts a protective activity against muscle wasting. This direct activity is independent of GHSR-1a and is shared by the unacylated form of ghrelin, which does not bind GHSR-1a and is devoid of the effects on appetite and GH release.

Summary: Both the acylated and unacylated forms of ghrelin might have therapeutic potential for the treatment of skeletal muscle wasting.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.